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Endoscopic resection is a suitable 
initial treatment strategy 
for oxyntic gland adenoma 
or gastric adenocarcinoma 
of the fundic gland type
Masaya Iwamuro1*, Chiaki Kusumoto2, Masahiro Nakagawa3, Sayo Kobayashi4, 
Masao Yoshioka5, Tomoki Inaba6, Tatsuya Toyokawa7, Shinichiro Hori8, Shouichi Tanaka9, 
Kazuhiro Matsueda10, Takehiro Tanaka11 & Hiroyuki Okada1 
The aim of this study was to reveal the histological features of oxyntic gland adenomas and gastric 
adenocarcinoma of the fundic-gland type (GA-FG). We retrospectively examined the histological 
features of 126 lesions of oxyntic gland adenoma and/or GA-FG in 116 patients. The prevalence 
of oxyntic gland adenomas and GA-FG was approximately equal. The majority of the lesions were 
resected by endoscopic mucosal resection using a diathermic snare (EMR, n = 42) or endoscopic 
submucosal dissection (ESD, n = 72). Histologically, there were no lesions with invasion at the level of 
the muscularis propria or deeper, and lymphovascular invasion was present in 1.6%. Of the ESD and 
EMR specimens, there were no lesions that were positive for vertical margins. Among the eight GA-FG 
patients with deep (≥ 500 μm) submucosal invasion, six were treated with endoscopic resection alone, 
and no recurrence was documented. No patients died of the disease during the median follow-up 
period of 14.5 months. In conclusion, all lesions were confined to the mucosa or submucosa and were 
negative for vertical margins. Lymphovascular invasion was present in only 1.6% of the patients. Thus, 
we believe that endoscopic resection is a suitable initial treatment method for oxyntic gland adenoma 
and GA-FG.
Abbreviations
eCuraC-2  Endoscopic curability C-2
EMR  Endoscopic mucosal resection using a diathermic snare
ESD  Endoscopic submucosal dissection
GA-FG  Gastric adenocarcinoma of the fundic gland type
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Gastric adenocarcinoma of the fundic gland type (GA-FG) is an epithelial neoplasm composed of columnar 
cells with differentiation to chief cells, parietal cells, or both. Since GA-FG was first reported as a single case 
report in  20071, histological, clinical, endoscopic, and genetic features have been investigated and documented in 
multiple case reports and case  series2–21. With the increasing popularity of the disease concept, GA-FG has been 
formally cited as a variant of gastric adenocarcinoma in the latest version of the classification of gastric neoplasms 
issued by the World Health Organization (WHO)22. Historically, this disease entity was variably named gastric 
adenocarcinoma with chief cell  differentiation1,5, gastric neoplasia of the fundic gland (chief cell-predominant) 
 type2,7,9, gastric fundic gland-associated neoplasms/polyps13, gastric adenocarcinoma of the fundic gland (chief 
cell predominant type)14,16, and chief-cell predominant gastric  polyps15. According to the WHO classification, 
a neoplasm confined to the mucosa is called an oxyntic gland adenoma, while a neoplasm with submucosal 
invasion is classified as GA-FG22. Due to their infrequency, treatment strategies for oxyntic gland adenoma and 
GA-FG have not yet been established. In this study, we included 126 lesions of oxyntic gland adenoma and/or 
GA-FG from 116 patients across 10 institutions and retrospectively examined the histological features, which is 
an essential step in the determination of an appropriate initial treatment strategy. The clinical and endoscopic 
features of this disease have also been summarized.
Methods
Letters of inquiry were sent to nine collaborating institutions with patients with histologically diagnosed oxyntic 
gland adenoma and GA-FG, from the Department of Gastroenterology and Hepatology, Okayama University 
Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences. Histological diagnoses were made based 
on endoscopic biopsy, endoscopic mucosal resection, endoscopic submucosal dissection, and/or surgical resec-
tion. The diagnoses of oxyntic gland adenoma and GA-FG were made based on the presence of intramucosal 
proliferation of differentiated columnar cells with pale basophilic cytoplasm and mild nuclear atypia, which 
have been found to mimic the oxyntic (fundic)  gland22. The diagnoses were supported by positive immunohisto-
chemical staining for pepsinogen I and MUC6 in some patients. We identified 116 patients who were diagnosed 
with oxyntic gland adenoma and/or GA-FG between October 2008 and February 2020. These patients were 
retrospectively enrolled in the study.
We retrospectively examined the patients’ sex, age at diagnosis, Helicobacter pylori infection status, endoscopic 
features, histological features, treatments, and prognoses. In patients with two or more lesions, a second or third 
primary lesion identified within 12 months of the detection of the first lesion were defined as “synchronous” 
multifocal lesions, while those identified more than 12 months after the detection of the first lesion were clas-
sified as “metachronous” multifocal lesions. H. pylori infection status was examined by urea breath tests, rapid 
urease tests, microscopic observations or culture tests on endoscopically biopsied specimens, stool antigen tests, 
serum or urine antibody tests, or a combination of these methods. Based on these test results, H. pylori infection 
status was classified into one of three groups: (i) uninfected (the gastric mucosa has never been infected by H. 
pylori), (ii) active gastritis (the gastric mucosa is currently infected by H. pylori), and (iii) inactive-gastritis (the 
gastric mucosa was previously infected by H. pylori, but H. pylori was absent following eradication treatment or 
spontaneous loss due to advanced atrophy).
Lesion morphologies and depth of invasion were classified according to the Japanese Classification of Gas-
tric  Carcinoma23,24. Briefly, polypoid-protruding tumors were classified as type 0–I. Slightly elevated superficial 
tumors were defined as type 0–IIa. Superficial flat tumors without elevation or depression were classified as type 
0–IIb. Slightly depressed tumors were defined as type 0–IIc. Excavated tumors with depressions were classified 
as type 0–III. In terms of the invasion depth, T1a represents a tumor confined to the mucosa, T1b1 indicates a 
tumor with invasion < 500 μm from the muscularis mucosa, and T1b2 is a tumor invading ≥ 500 μm from the 
muscularis mucosa. The follow-up period was defined as the time from endoscopic or surgical resection of gastric 
lesions to death from any cause or the last hospital visit. The endoscopic follow-up period was defined as the time 
from endoscopic or surgical resection of gastric lesions to the last esophagogastroduodenoscopy examination.
The primary purpose of this study was to measure the prevalence of submucosal (T1b1/T1b2), vascular, and 
lymphatic invasion in oxyntic gland adenoma and GA-FG patients in order to determine the appropriate initial 
treatment strategy. Patients’ clinical and endoscopic characteristics, as well as their prognostic outcomes, were 
also reviewed.
This study was approved by the Ethics Committees of Okayama University Hospital and other institutions 
and adhered to the Declaration of Helsinki. Written informed consent was waived because of the observational, 
non-interventional, and retrospective design. All investigations were performed in accordance with the relevant 
guidelines and regulations.
Results
The patient characteristics are listed in Table 1. This study included 75 men and 41 women. The mean age at 
diagnosis of oxyntic gland adenoma or GA-FG was 66.4 years (range 46–91 years), and 101 patients were 60 years 
or older (87.1%). Most patients (n = 108, 93.1%) had a single lesion, six patients (5.2%) had two lesions, and 
two patients (1.7%) had three lesions. Among the 8 patients with multifocal lesions, synchronous occurrence 
of oxyntic gland adenoma or GA-FG was observed in 7 patients, while the remaining patients presented with 
two metachronously developed lesions that were diagnosed 13 months apart. Thus, 126 lesions of oxyntic gland 
adenoma or GA-FG were included in this study.
Representative endoscopic images of oxyntic gland adenoma and GA-FG are shown in Fig. 1, and the endo-
scopic features of the 126 lesions are listed in Table 2. Oxyntic gland adenoma and GA-FG were most frequently 
observed in the gastric body (n = 66, 52.4%), followed by the fornix (n = 38, 30.2%) and cardia (n = 21, 16.7%). 
Among the lesions developing in the gastric body, 34 lesions were found in the upper third portion, 24 lesions 
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Table 1.  Clinical characteristics of the study population. *n = 113. ESD, endoscopic submucosal dissection; 










H. pylori infection status
Uninfected 38 30.2
Active gastritis 13 10.3






ESD followed by surgery 2 1.6
None 7 5.6
Median follow-up period (range), months 14.5 (0–107)
Median endoscopic follow-up period (range), months* 11 (0–107)
Outcome
Alive 112 96.6
Died of other cause 3 2.6
Unknown 1 0.9
Figure 1.  Representative endoscopic images of oxyntic gland adenoma and/or gastric adenocarcinoma of 
fundic-gland type. (A) A typical image of oxyntic gland adenoma showing a slightly whitish, elevated lesion of 
5 mm, with vascular dilatation on the surface. (B) A representative image of gastric adenocarcinoma of fundic-
gland type (T1b1) presented as a slightly yellowish, elevated lesion of 7 mm, with vascular dilatation. (C) An 
oxyntic gland adenoma showing a flat, whitish lesion (linked color imaging). (D) A gastric adenocarcinoma of 
fundic-gland type (pT1b1) showing a flat lesion. The color of the lesion is similar to that of the peripheral gastric 
mucosa. (E) Gastric adenocarcinoma of fundic-gland type (T1b2) presented as the largest tumor (25 mm, 
arrows). The lesion is composed of swollen gastric folds and a whitish, depressed area in the center (arrowhead). 
Vascular dilatation is observed throughout the lesion. (F) A gastric adenocarcinoma of fundic-gland type 
(pT1b1) accompanying black pigmentation (arrows).
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in the middle third portion, and 8 lesions in the lower third portion. No lesions were identified in the gastric 
antrum or pylorus. The mean lesion size was 6.2 mm (range 2–25 mm). Notably, the lesion size was 10 mm 
or less in 117 lesions (92.9%). Oxyntic gland adenoma and GA-FG appeared as 0–IIa (n = 72, 57.1%), 0–IIb 
(n = 39, 31.0%), 0–IIc (n = 9, 7.1%), 0–IIa + IIc (n = 4, 3.2%), or 0–I (n = 2, 1.6%). Macroscopically, 64 lesions 
(50.8%) exhibited a subepithelial lesion. The color of the lesion was similar to that of the peripheral mucosa 
(n = 49, 38.9%), yellowish-white (n = 34, 27.0%), whitish (n = 22, 17.5%), reddish (n = 14, 11.1%), or yellowish 
(n = 7, 5.6%). Vascular dilatation was present on the surface of 81 lesions (64.3%), and black pigmentation was 
observed in 18 lesions (14.3%). 
The histological features of oxyntic gland adenoma and GA-FG are listed in Table 3, and typical histological 
images of GA-FG are shown in Fig. 2. Information on the depth of invasion was available for 107 lesions; 51 
lesions were T1a (40.5%), 48 lesions were T1b1 (38.1%), and 8 lesions were T1b2 (6.3%). No lesions invaded 
the muscularis propria or deeper. Vascular invasion was present in 1/104 lesions (0.8%), and lymphatic inva-
sion was present in 1/106 lesions (0.8%). Immunohistochemistry showed that 67/71 lesions were positive for 
pepsinogen I (94.4%), 71/82 lesions were positive for MUC6 (86.6%), of 24/39 lesions were positive for  H+/
K+-ATPase (61.5%), and 9/73 lesions were positive for MUC5AC (12.3%). No lesions were positive for MUC2 
(0/23, 0.0%) or CD10 (0/15, 0.0%).
Oxyntic gland adenoma and GA-FG were resected by endoscopic submucosal dissection (ESD, n = 72, 57.1%), 
endoscopic mucosal resection using a diathermic snare (EMR, n = 42, 33.3%), surgery (n = 3, 2.4%), or ESD fol-
lowed by surgery (n = 2, 1.6%) (Table 1). EMR in one patient resulted in a partially positive horizontal margin, 
while none of the patients had positive vertical margins. One patient with T1b2 GA-FG underwent additional 
surgery after ESD according to the attending physician’s recommendation. The other patient with T1b1 GA-FG 
underwent surgical resection after ESD at the patient’s request. No lymph node metastases were observed in 
the surgically resected specimens. During the median follow-up period of 14.5 months (range 0–107 months), 
112 patients were still alive (96.6%), while three patients died of causes other than oxyntic gland adenoma or 
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GA-FG (2.6%), including cecal cancer, small intestine cancer, and recurrence after cholangiocellular carcinoma. 
The outcomes of the remaining patients were unavailable. Repeat esophagogastroduodenoscopy was performed 
in 113 lesions (89.7%), with a median endoscopic follow-up period of 11 months (range 0–107 months). Local 
recurrence was identified in 2 patients. Although the initial lesion was confined to the mucosa (T1a), EMR in 
one patient resulted in a positive horizontal margin, and recurrence of oxyntic gland adenoma was noted on 
the stomach scar 45 months after the initial treatment. The other patient also had recurrence of oxyntic gland 
adenoma on the stomach scar, despite curative resection of the initial lesion by ESD with negative horizontal 
and vertical margins and no lymphatic or vascular invasion. Both patients underwent no additional treatment 
and were followed up with endoscopic and radiological examinations.
When considering the 8 patients with T1b2 GA-FG (Table 4), one patient underwent surgical resection and 
another patient underwent ESD followed by surgery, while 5 patients were treated with ESD alone, and the 
remaining patient was treated with EMR alone. In the 6 patients who underwent ESD or EMR alone, no dis-
tant metastases or recurrences were identified during the median endoscopic follow-up period of 10.5 months 
(0–54 months).
Discussion
To our knowledge, this study included the largest number of patients with oxyntic gland adenoma and/or GA-FG. 
Based on histological analyses, 51 lesions were confined to the muscularis propria, and submucosal invasion was 
identified in 56 lesions. Thus, the prevalence of oxyntic gland adenoma and GA-FG was approximately equal 
in this study. In 111 reported cases, Benedict et al. showed that the invasion depth reached the mucosa (n = 31), 
muscularis mucosae (n = 1), submucosa (n = 63), serosa (n = 1), muscularis propria (n = 1), and undetermined 
(n = 14)25. Thus, the incidence rates of oxyntic gland adenoma and GA-FG were estimated to be 1:222. The dis-
crepancy in the prevalence between our study and previous reports may have been caused by publication biases 
because more lesions with submucosal invasion (GA-FG) may be published than those confined within the 
mucosa (oxyntic gland adenoma). In the present study, most of the lesions were resected using either ESD or 
EMR (n = 114, 90.5%). There were no lesions with invasion at the level of the muscularis propria or deeper, and 
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lymphovascular invasion was present in only 1.6% of lesions. Although EMR resulted in a positive horizontal 
margin in one patient, there were no lesions with exposed tumor cells in the vertical margins of the endoscopic 
resection specimens. These results indicate that endoscopic resection is a suitable initial treatment strategy for 
oxyntic gland adenoma and GA-FG.
Notably, 6 of the 8 GA-FG patients with deep submucosal invasion (T1b2) were followed up without addi-
tional surgical resection after endoscopic treatment. No recurrence was documented at a median endoscopic 
follow-up period of 10.5 months. In Japanese gastric cancer treatment guidelines, endoscopically resected-T1b2 
tumors are defined as endoscopic curability C-2 (eCuraC-2), and gastrectomy with lymphadenectomy should be 
 considered23,24. Despite the recommendations described in these guidelines, most attending physicians followed 
Figure 2.  Typical histological images of a gastric adenocarcinoma of fundic-gland type (pT1b1). Endoscopic 
submucosal dissection specimen of Fig. 1F. (A) Neoplastic cells form a more complex gland structure 
(hematoxylin and eosin staining, × 4.2, arrow), compared to their normal oxyntic counterparts (right portion of 
image). The neoplastic cells are mainly observed in the deeper portion of the mucosa and covered with foveolar 
epithelium. (B) Tumor cells are composed of highly differentiated columnar cells with mild nuclear atypia and a 
pale basophilic cytoplasm (hematoxylin and eosin staining, × 20). Brown to black pigments are observed in the 
dilated glands lined by the neoplastic cells (arrow). (C) The tumor cells are positive for pepsinogen-I. (D) The 
tumor cells are partially positive for  H+/K+-ATPase.
Table 4.  Characteristics of the patients with submucosal invasion of 500 μm or more (T1b2). F female, M 
male, ESD endoscopic submucosal dissection, EMR endoscopic mucosal resection using a diathermic snare, 
N/A not applicable.
Case no Sex
Age at diagnosis 








1 F 76 0–IIa 7 ESD 870 29 None 61 Alive
2 F 66 0–IIa + IIc 15 ESD 2700 54 None 64 Dead by other cause
3 M 59 0–IIa + IIc 10 ESD 880 19 None 21 Alive
4 M 86 0–IIa 15 ESD 900 0 None 2 Alive
5 M 64 0–IIa 12 ESD 649 0 None 0 Alive
6 M 55 0–I 5 EMR 640 2 None 2 Alive
7 M 46 0–IIa + IIc 25 Surgery > 500 N/A None 0 Alive
8 M 61 0–IIa + IIc 15 ESD followed by surgery > 500 14 None 14 Alive
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up with the patients. These decisions were probably supported by the fact that the neoplastic cells in the submu-
cosa can be regarded as “prolapse-type” misplaced glands showing minimal desmoplastic changes, rather than 
true submucosal  invasion21,25. However, further investigations with longer observation periods are required to 
elucidate the appropriate treatment strategies for oxyntic gland adenoma and GA-FG.
Although some debate remains regarding the biological behavior of oxyntic gland adenoma and GA-FG, it is 
widely accepted that this gastric neoplasm rarely affects lymphatic and vascular systems and grows  slowly8,9,12,14,15. 
Lymphatic and/or vascular invasion was positive in 7/94 reported cases (7.4%)25 and 2/126 in the present study 
(1.6%). Additionally, no patients died of oxyntic gland adenoma or GA-FG in our study or in previous reports. 
These data suggest that oxyntic gland adenoma and GA-FG are neoplasms with low malignant potential, resulting 
in a favorable prognosis. Thus, discussions are still ongoing on the correct  nomenclature25 and some pathologists 
favor terms, such as “oxyntic gland adenomas,” “fundic gland adenoma,” or “fundic gland polyps with chief or 
parietal cell differentiation,” in place of “adenocarcinoma.” In contrast, a patient with GA-FG infiltrating into 
the subserosa with lymphatic and venous invasion has been  reported10. Ushiku et al. proposed that GA-FG with 
atypical cellular differentiation, such as mucous neck cells and foveolar epithelium in addition to chief cells and 
parietal cells, be subcategorized as “adenocarcinoma of fundic gland mucosa type” as they are probably a more 
aggressive  phenotype21. Since lesions of oxyntic gland adenoma and GA-FG are likely to be heterogeneous, it is 
necessary to establish appropriate histological subcategorization and terminology.
We revealed that these neoplasms developed in patients aged 60 years or older in most cases (87.1%), with a 
male-to-female ratio of approximately 2:1. Male predominance and frequent occurrence in patients aged 60 years 
or older has been previously  reported14,22,25. Oxyntic gland adenoma and GA-FG mostly occurred solely (93.1%), 
with the development of two or three lesions occurring in a limited number of patients. As the second and third 
lesions were identified within 12 months from the diagnosis of the initial lesion, except in one patient, careful 
observation is recommended during esophagogastroduodenoscopy to avoid overlooking other lesions of oxyntic 
gland adenoma and GA-FG. H. pylori infection reportedly has no association with the development of these 
 lesions22,25. Chiba et al. reported that among 20 patients with oxyntic gland adenoma or GA-FG, 5 patients were 
uninfected with H. pylori (25.0%), while the remaining 15 patients had active or inactive gastritis (75.0%)14. We 
also revealed that the H. pylori infection status varied from inactive gastritis (47.6%) and uninfected (30.2%) to 
active gastritis (10.3%). These results reinforce the hypothesis that oxyntic gland adenoma or GA-FG develops 
irrespective of H. pylori infection status.
The typical endoscopic features of oxyntic gland adenoma or GA-FG are known as a whitish small elevation 
of < 10 mm in diameter, with irregular branching vessels, predominantly occurring in the upper third portion 
of the  stomach14,22,25. In the present study, 73.8% of the lesions were found in the upper third portion of the 
stomach (i.e., the fornix, cardia, and upper third of the body), while the other lesions were identified in the 
middle third portion (i.e., the middle to lower third of the body and angle). No lesions were observed in the 
lower third portion of the stomach. The lesion size was 10 mm or less in most cases (92.9%). A slightly elevated 
superficial morphology accounted for more than half of the lesions (57.1%), and a flat tumor, without elevation 
or depression, represented approximately one-third of the lesions (31.0%). Half of the lesions showed a subepi-
thelial lesion (50.8%). Vascular dilatation was present on the surface of approximately two-thirds of the lesions 
(64.3%). Although the color of the lesions in oxyntic gland adenoma and GA-FG varied from a color similar to 
the peripheral mucosa, to yellowish-white, white, reddish, and yellowish, the macroscopic features observed in 
the present study were consistent with those reported  previously22,25. Brownish or black pigmentation has been 
described in several case  reports12,17,19, which are considered to reflect pigmented substances contained in the 
dilated glands of neoplastic cells (Fig. 2B). Such pigmentation was identified in 14.3% of lesions in this study.
This study had several limitations. First, endoscopic and histological analyses were performed at various 
institutions. It is possible that interobserver variations and differences in methodologies between the participating 
institutions may have resulted in heterogeneous patient data. However, our results could be generalized to institu-
tions worldwide. Second, the follow-up period following diagnosis of oxyntic gland adenoma and/or GA-FG was 
relatively short (median 14.5 months), resulting in insufficient analysis of patient outcomes. Complete follow-up 
with a longer observation period should be considered in future investigations. Third, immunohistochemical 
studies were not performed for all patients. Although diagnosis can essentially be made according to the WHO 
classification criteria based on the presence of intramucosal proliferation of differentiated columnar cells with 
pale basophilic cytoplasm and mild nuclear atypia that mimics the oxyntic gland, it is preferably, however, con-
firmed by positivity for both pepsinogen I and  MUC622. Cell differentiation markers, such as  H+/K+-ATPase 
(parietal cell) and MUC5AC (foveolar epithelium), will help in the diagnosis of the adenocarcinoma of the fun-
dic gland mucosa  subtype21. In addition, D2-40-based assessment improves the histopathological detection of 
lymphovascular invasion. Fourth, histological and patient information was incomplete due to the retrospective 
nature of this study; the mucosa adjacent to oxyntic gland adenoma or GA-FG is reportedly normal without 
any intestinal metaplasia or  atrophy9. Additionally, several researchers have suggested a possible relationship 
between acid suppressive therapy and the pathogenesis of oxyntic gland adenoma and GA-FG. Future studies 
incorporating such histological and patient information may reveal a more detailed pathophysiology of these 
gastric neoplasms.
In conclusion, we retrospectively investigated 116 patients with 126 lesions of oxyntic gland adenoma or 
GA-FG. The majority of oxyntic gland adenomas and GA-FG cases were resected using ESD or EMR. Histologi-
cally, there were no lesions with invasion at the level of the muscularis propria or deeper, and lymphovascular 
invasion was present in only 1.6% of lesions. Of the ESD/EMR specimens, no lesions were positive for vertical 
margins. Based on these results, we believe that endoscopic resection is a suitable initial treatment strategy for 
oxyntic gland adenoma and GA-FG. Although most of the T1b2 GA-FG patients were treated with endoscopic 
resection alone and no recurrence was documented, further investigations are required to elucidate the optimal 
treatment strategy for T1b2 GA-FG.
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Data availability
The datasets generated and/or analyzed during the current study are available from the corresponding author 
upon reasonable request.
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